A SERVICE OF U.S. NATIONAL INSTITUTES OF HEALTH
We are pleased to announce that $20,000 has been granted to support Dr. Rutka's research project - Identification and characterization of immunotherapeutic targets in diffuse intrinsic pontine gliomas and $10,000 has been grnated to support this clinical trial - A safety and feasibility study to evaluate Blood-Brain Barrier(BBB) Disruption Using Transcranial MRI-Guided Focused Ultrasound with Intravenous Ultrasound Contrast Agents and Chemotherapy in the patients with Diffuse Intrinsic Pontine Gliomas.
We will be given the opportunity to meet with Dr. Rutka & Dr. Ramaswamy later this year to get an update on their progress with their research.
Dr. Annie Huang, senior scientist and neurooncologist at SickKids, led in an unbelievable discovery published in Cancer Cell in the pursuit of breakthroughs for patients with a rare tumour called ETMR. ETMR’s are distinctly hard-to-treat infantile brain tumours with a very poor rate of survival. Dr. Huang and team studied developmental pathways in these tumours, and have identified a specific and major driver in the disease. This has led to the identification of a new therapeutic target to attack and kill ETMRs, reaffirming hope for patients with this tragic type of tumour. Next steps will be to get this study into clinical trials.
When we first started fundraising in November 2016, we set up a SickKids tribute page dedicated to DIPG research and within a year we had raised over $48,000. We realized that this would be something that we would do long term and wanted to have a bigger impact in memory of our daughter Nelina. Her DIPG journey was always one of hope, and now her legacy. To view the SickKids tribute page, or to donate directly to SickKids DIPG research fund, click below.
CANADIAN CANCER TRIALS
We are pleased to announce the 2018 Small Grant Recipient is Dr. Vijay Ramaswamy, a Junior PI and staff oncologist at SickKids Hospital in Toronto. The research project that this grant will support is Overcoming radiation resistance in high-risk pediatric brain tumors. The research will approach radiation resistance to determine which components of DNA Damage Response pathway are required for repair by radiation induced damage. Various approaches will be used in parallel using various drug inhibitors to determine if cells can become more sensitive to radiation treatment. The research will approach high risk brain tumors such as RELA fused supratentorial ependymoma followed by ATRT and DIPG.
We are pleased to announce that $25,000 has been granted to Dr. Cynthia Hawkins, Senior Scientist and Principal Investigator at SickKids Hospital in Toronto. Her current DIPG research is working on understanding a recurrent mutation H3-K27M and to create model interactions as to how these genetic alterations drive tumor formation. This research will potentially lead to the foundation of preclinical models to test new therapies and set the stage for stratified, subgroup-tailored clinical trials.
Our second grant of $10,000 has been awarded to Dr. Anne Huang, the lead at the Rare Brain Tumor Consortium (RBTC) at SickKids Hospital in Toronto, Canada. This registry will be instrumental in accelerating advancement in understanding rare and typically fatal brain tumors. Over 70 centres around the world contribute to this registry. By providing funding to this registry, funds will support ongoing collection, storage and research of rare brain tumor samples. This amalgamation of samples provides researchers from around the world to advance their research because of the increased samples that are available.
Over $180,000 raised since November 2016 and creating hope one donation at a time.
Donation was made in memory of
Malcom, Benny, Emmanuel and Avril Moore
Research led by SickKids and St. Michael’s Hospital in Toronto has proven that a protein (called ID1) is critical to the growth and development of glioblastoma, and also has an effect on the tumour’s response to chemo. Glioblastoma, the brain cancer that killed the late Tragically Hip singer Gord Downie and U.S. Sen. John McCain, is an aggressive form of brain cancer and is extremely difficult to treat. Therapy generally involves the combination of several approaches to control the disease, but there is currently no known cure. This new study, published this week in Cancer Research, found that the ID1 protein helps maintain cancer stem cells in glioblastoma, making them less susceptible to treatment. But when they "turned off" the ID1 protein in lab models, glioblastoma tumours slowed down. The team also learned that turning off the protein meant tumours were less resistant to chemotherapy.The next steps for this research are to look at the development of new medications and test them in clinical trials.
There are ongoing pediatric brain cancer research projects and clinical trials being conducted around the world. Here is some of the most recent published research being conducted today in hopes of understanding the drivers of brain tumors and finding treatment options. These research articles, journals and extractions are not to be considered inclusive of all research but to highlight the research and clinical trials being conducted around the world.